← Back to Search

Behavioral Intervention

CGM Toolkit Training for Diabetes

N/A

Waitlist Available

Led By Emily Schmied,, PhD

Research Sponsored by San Diego State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Current patient of one of the three participating Innercare Clinics with no plans to discontinue care at Innercare within the next 6 months

Be older than 18 years old

Must not have

Patients with newly diagnosed diabetes mellitus (less than one year), diabetes insipidus, diabetes type 1, or gestational diabetes

Timeline

Screening 3 weeks

Treatment Varies

Follow Up clinic implementation to month 9

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to see if training healthcare professionals increases the number of continuous glucose monitor prescriptions for Type 2 Diabetes patients in a Hispanic/Latino community health center. They will also study if using a

Who is the study for?

This trial is for healthcare professionals at clinics serving a predominantly Hispanic/Latino population, with the goal of increasing continuous glucose monitor (CGM) prescriptions for patients with Type 2 Diabetes. Patients participating must have Type 2 Diabetes and be attending these clinics.

What is being tested?

The study tests if training healthcare providers on CGM guidelines and insurance eligibility can boost CGM prescription rates. It also examines whether having a CGM affects diabetes control in patients, measured by Hemoglobin A1c levels.

What are the potential side effects?

Since this trial focuses on professional training rather than direct medical interventions, there are no traditional side effects involved. However, patient surveys will assess any barriers or difficulties encountered when using prescribed CGMs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am currently seeing a doctor at Innercare and plan to continue for at least 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I was diagnosed with diabetes less than a year ago, or I have diabetes insipidus, type 1 diabetes, or gestational diabetes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ clinic implementation to month 9

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~clinic implementation to month 9

This trial's timeline: 3 weeks for screening, Varies for treatment, and clinic implementation to month 9 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

CGM prescription rates

Secondary study objectives

Challenges and Facilitators to CGM Uptake in Patients with T2D

Effect of CGM Prescription on HgbA1C

Effect of CGM on Individual Diabetes Distress Among Patients with T2D

+1 more

Other study objectives

HCP/Staff Experiences with Prescribing & Monitoring CGM use in Target Population

Participant Experience with Prescribing, Acquiring and/or Using a CGM.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Healthcare Prescribers Exposed to CGM Prescriber Toolkit TrainingExperimental Treatment1 Intervention

Participants in this arm will include qualified healthcare prescribers (MDs, DOs, PAs, NPs, etc.) and staff who treat patients with Type 2 diabetes in primary care settings who will receive in depth training using a study-developed prescriber toolkit. The toolkit covers important information including current clinical practice guidelines, eligibility criteria, provider documentation requirements and scripts for discussing CGM use with their patient population. The impact of the training will be evaluated by examining changes in CGM prescription rates for patients with Type 2 diabetes seen in primary care before and after the training is delivered. Secondarily, Participants will be surveyed pre- and post-training to elicit prescribing knowledge and attitudes towards CGM use.

Group II: Healthcare Prescribers Not Exposed to CGM Prescriber Toolkit TrainingActive Control1 Intervention

Participants in this arm are prescribers (MDs, DOs, PAs, NPs, etc.) and staff who will NOT receive in depth training using a study-developed prescriber toolkit.

0 / 2Eligibility criteria met